Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Beyond Air ( (XAIR) ).
On February 13, 2026, Beyond Air reported fiscal third-quarter 2026 results for the period ended December 31, 2025, with revenue more than doubling year over year to $2.2 million, driven by growing demand for LungFit PH in the U.S. and abroad, including its first sale into a VA Medical Center. The company expanded its LungFit PH distribution network to 40 countries, tightened operating expenses, narrowed its net loss to $7.3 million, and ended the quarter with $17.8 million in cash and securities, augmented to a pro forma $22.3 million after a January private placement that management believes funds operations into 2027.
Beyond Air highlighted regulatory and strategic milestones, including pending FDA review of a second-generation LungFit PH system, international submissions, and clinical progress in its UNO solid tumor program, whose Phase 1a monotherapy data will be presented at the AACR 2026 meeting. The company also entered a binding deal under which XTL Biopharmaceuticals will acquire 85% of its NeuroNOS subsidiary, positioning NeuroNOS as XTL’s flagship neuro-oncology and autism platform and potentially delivering up to $32.5 million in consideration to Beyond Air, while recent leadership changes and balance-sheet moves aim to support its next phase of commercial and R&D growth.
The most recent analyst rating on (XAIR) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.
Spark’s Take on XAIR Stock
According to Spark, TipRanks’ AI Analyst, XAIR is a Neutral.
The score is primarily constrained by very weak profitability and pressured cash flow despite revenue growth, alongside elevated leverage. Technicals are mixed with the stock below longer-term averages, while earnings-call updates (growth, cost/burn reductions, distribution expansion) provide some support but not enough to offset current financial strain.
To see Spark’s full report on XAIR stock, click here.
More about Beyond Air
Beyond Air, Inc., based in Garden City, N.Y., is a commercial-stage medical device and biopharmaceutical company focused on harnessing nitric oxide to treat respiratory and oncologic diseases. Its lead commercial product is the LungFit PH tankless nitric oxide delivery system for hospital-based use, and it is also advancing an intratumoral ultra-high concentration nitric oxide (UNO) platform for solid tumors through its Beyond Cancer subsidiary.
Average Trading Volume: 7,609,733
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.95M
For an in-depth examination of XAIR stock, go to TipRanks’ Overview page.